Skip to navigation Skip to content

Systemic lupus erythematosus (SLE) Program in Pharmaceutical Benefits Scheme (PBS) 012-24060528

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised anifrolumab for patients with systemic lupus erythematosus (SLE).

SLE and listing dates

SLE is a chronic autoimmune disease that can affect many parts of the body and cause inflammation and tissue damage.

Listing dates: anifrolumab - 1 July 2024.

See Written Authority Required Drugs, for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • item and restriction codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority approval requests

Written Authority Required Drugs